title: Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome.
abstract: BACKGROUND
  Efficacy and long-term outcome of antiviral therapy for recurrent hepatitis C after liver transplantation is poorly defined.
  
  
  OBJECTIVE
  This study aimed at assessing the efficacy of antiviral therapy regarding sustained hepatitis C virus (HCV) clearance, liver histology, and patient survival.
  
  
  METHODS
  We retrospectively reviewed all 446 patients who received a liver allograft at our institution for HCV-related cirrhosis between January 1992 and December 2006. Two hundred thirty-two patients (52%) were eligible for antiviral therapy based on predefined criteria (Metavir stage > or =1 and/or grade > or =2; protocol biopsies). One hundred seventy-two patients (39%) had no contraindication for treatment, received more than or equal to 1 dose of interferon-alpha-based combination therapy, and form the basis of this analysis. Therapy was aimed for 48 weeks; median posttreatment follow-up was 68 months.
  
  
  RESULTS
  The overall sustained virological response (SVR) rate was 50% (genotype 1/4: 40%; genotype 2/3: 76%). SVR was higher on cyclosporine A (CsA) (56%) than on tacrolimus (44%, P=0.05), largely because of a lower relapse rate (6% vs. 19%, P=0.01). In multivariate analysis, genotype 2/3, CsA use, donor age, and pretreatment necroinflammatory activity were independently associated with SVR. SVR significantly improved histology and long-term survival (actuarial 5-year survival 96% vs. 69% in nonresponders, P<0.0001).
  
  
  CONCLUSIONS
  Antiviral therapy of recurrent hepatitis C after liver transplantation is able to clear HCV in half the patients, more likely on CsA than on tacrolimus, and markedly improves outcome.
authors.affiliation: Multi-organ Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.
authors.forename: Nazia
authors.initials: N
authors.lastname: Selzner
authors.forename: Eberhard L
authors.initials: EL
authors.lastname: Renner
authors.forename: Markus
authors.initials: M
authors.lastname: Selzner
authors.forename: Oyedele
authors.initials: O
authors.lastname: Adeyi
authors.forename: Arash
authors.initials: A
authors.lastname: Kashfi
authors.forename: George
authors.initials: G
authors.lastname: Therapondos
authors.forename: Nigel
authors.initials: N
authors.lastname: Girgrah
authors.forename: Chaturika
authors.initials: C
authors.lastname: Herath
authors.forename: Gary A
authors.initials: GA
authors.lastname: Levy
authors.forename: Leslie
authors.initials: L
authors.lastname: Lilly
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006526:Hepatitis C / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D017093:Liver Failure / Q000601:surgery* / Q000821:virology; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012008:Recurrence; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors; D014019:Tissue Donors / Q000706:statistics & numerical data; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a; D016559:Tacrolimus